Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| American Diabetes Association | OTHER |
Not provided
Not provided
Not provided
Not provided
Severe hypoglycemia (low blood sugar)after gastric bypass surgery is an increasingly recognized condition, characterized by symptoms of hypoglycemia after eating and inappropriately elevated insulin concentrations that occur at the time of hypoglycemia. Severe hypoglycemia can be dangerous and debilitating and can also impact cognitive function. At the moment no medical therapies have been developed for this disorder. Determining why some but not other patients develop this condition would allow for improved prediction, prevention, and treatment approaches. The purpose of the study is to understand the physiological changes observed in those patients who undergo gastric bypass and develop symptomatic hypoglycemia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Remote Phase: Post-Bariatric Hypoglycemia Patients | Experimental | Participants will wear continuous glucose monitor (CGM) in a blinded manner (cannot see data output) for 20 days followed by in an unblinded manner (can see data output) for 20 days. |
|
| In-Clinic Phase: Post-Bariatric Hypoglycemia Patients | No Intervention | Participants will attend 1-3 study visits over the period of approximately 2 months, with metabolic parameters assessed under a variety of conditions. This group will also wear CGM during a portion of the metabolic tests. This may include participants from the Remote Phase or newly enrolled participants. | |
| In-Clinic Phase: Surgical Controls | No Intervention | Participants will attend 1-3 study visits over the period of approximately 2 months, with metabolic parameters assessed under a variety of conditions. | |
| In-Clinic Phase: Nonsurgical Controls | No Intervention | Participants will attend 1-3 study visits over the period of approximately 2 months, with metabolic parameters assessed under a variety of conditions. | |
| In-Clinic Phase: Post-Bariatric Hypoglycemia Patients with indwelling gastrostomy tube | No Intervention | Participants will undergo standardized mixed meal tolerance tests via oral, gastrostomy tube, and concomitant oral + gastrostomy tube routes of delivery with metabolic parameters assessed. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Use of Continuous Glucose Monitor (CGM) | Behavioral | Participants will wear CGM |
|
| Measure | Description | Time Frame |
|---|---|---|
| Steady state plasma glucose (SSPG) as a measure of insulin sensitivity | This endpoint applies to the In-Clinic Phase cohorts: Post-Bariatric Hypoglycemia, Surgical Controls, Non-Surgical Controls. This is a one day in-person appointment lasting approximately 6 hours. | Baseline 4-hour SSPG |
| Rate of gastric emptying | This endpoint applies to the In-Clinic Phase cohorts: Post-Bariatric Hypoglycemia, Surgical Controls, Non-Surgical Controls. This is an in-person appointment lasting approximately 5 hours. | Baseline 4-hour scintigraphy procedure |
| Concentration of Glucagon-Like peptide 1 secretion augmentation of insulin secretion rate | This endpoint applies to the In-Clinic Phase cohorts: Post-Bariatric Hypoglycemia, Surgical Controls, Non-Surgical Controls. The blood collected from the SSPG will be stored and analyzed for the concentration of GLP-1 at multiple timepoints. | Baseline 4-hour graded-glucose infusion |
| Rate of clinically important hypoglycemia (Level 2 hypoglycemia, <54 mg/dL) | This endpoint applies to Remote Phase participants | 40 days |
| Percent time in clinically important hypoglycemia (Level 2 hypoglycemia, <54 mg/dL) | This endpoint applies to Remote Phase participants | 40 days |
| Rate of arrhythmia during hypoglycemia | This endpoint applies to Remote Phase participants | 10 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tracey McLaughlin, MD | Stanford University | Principal Investigator |
| Colleen Craig, MD | Stanford University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University School of Medicine | Recruiting | Stanford | California | 94305-5103 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Use of "Cardea Solo" monitoring | Other | Participants will wear a "Cardea Solo" patch during blinded CGM use |
|